StockMacro
Menu

Aptevo Therapeutics

$0.40 -92% in 6 monthsMarket cap $1.4M

APVO on XNAS, Health Care, Aptevo Therapeutics Inc, job postings

Measures activity, not value. Not investment advice.

Shares down 98% in 12 months while a share registration and a private offering were filed in 90 days.

  • BadNet loss of $25.4M over 12 months, against cash of $8.3M
  • WatchS-1 filers trailed their sector by median 23.8 points in 6 months

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Industry
Pharmaceutical preparations (Health Care)
Employees
33
Website
aptevotherapeutics.com
Listed
Nasdaq, US
Last results
16 Nov 2026
Next results
expected around 25 Mar 2027 (an estimate: a year ago it reported on 26 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $6.5M.
Quarter to 31 Dec 2021: revenue $3.7M, net income -$6.3MQuarter to 31 Dec 2021: revenue $3.7M, net income -$6.3MQuarter to 31 Mar 2022: revenue $3.1M, net income -$7.7MQuarter to 31 Mar 2022: revenue $3.1M, net income -$7.7MQuarter to 30 Jun 2022: revenue $0, net income $28.0MQuarter to 30 Jun 2022: revenue $0, net income $28.0MQuarter to 30 Sep 2022: revenue $0, net income -$7.6MQuarter to 30 Sep 2022: revenue $0, net income -$7.6MQuarter to 31 Dec 2022: revenue $0, net income -$4.6MQuarter to 31 Dec 2022: revenue $0, net income -$4.6MQuarter to 31 Mar 2023: revenue –, net income $2.8MQuarter to 30 Jun 2023: revenue –, net income -$7.9MQuarter to 30 Sep 2023: revenue –, net income -$6.3MQuarter to 31 Dec 2023: revenue –, net income -$5.9MQuarter to 31 Mar 2024: revenue –, net income -$6.8MQuarter to 30 Jun 2024: revenue –, net income -$5.9MQuarter to 30 Sep 2024: revenue –, net income -$5.1MQuarter to 31 Dec 2024: revenue –, net income -$6.3MQuarter to 31 Mar 2025: revenue –, net income -$6.4MQuarter to 30 Jun 2025: revenue –, net income -$6.2MQuarter to 30 Sep 2025: revenue –, net income -$7.5MQuarter to 31 Dec 2025: revenue –, net income -$5.8MQuarter to 31 Mar 2026: revenue –, net income -$6.7MQuarter to 30 Jun 2026: revenue –, net income -$6.4MQuarter to 30 Sep 2026: revenue –, net income -$6.5M
31 Dec 2021RevenueNet incomeNet losstallest bar $28.0M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$6.5M
30 Jun 2026–-$6.4M
31 Mar 2026–-$6.7M
31 Dec 2025–-$5.8M
30 Sep 2025–-$7.5M
30 Jun 2025–-$6.2M
31 Mar 2025–-$6.4M
31 Dec 2024–-$6.3M
30 Sep 2024–-$5.1M
30 Jun 2024–-$5.9M
31 Mar 2024–-$6.8M
31 Dec 2023–-$5.9M
30 Sep 2023–-$6.3M
30 Jun 2023–-$7.9M
31 Mar 2023–$2.8M
31 Dec 2022$0-$4.6M
30 Sep 2022$0-$7.6M
30 Jun 2022$0$28.0M
31 Mar 2022$3.1M-$7.7M
31 Dec 2021$3.7M-$6.3M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$25.4M -$26.5M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -239% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $8.3M $9.4M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$8.3M (net cash) -$9.4M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $1.11
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 0.36 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Aptevo TherapeuticsAPVO (this company) $1.4Mloss–––
PMGCELAB $1.3Mloss0.28–-276%
Artelo BiosciencesARTL $1.3Mloss–––
Jupiter NeurosciencesJUNS $1.6Mloss–––
Kala BIOKALA $1.7Mloss–––
Propanc BiopharmaPPCB $1.7Mloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

–

No data for this company

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

9.8%

339K shares held by 13F filers (30 Sep 2026) of 3.5M outstanding (16 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

2.1%

71K shares sold short (30 Oct 2026) of 3.5M outstanding (16 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

1.9

71K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-26%

97K shares sold short in the report before, 71K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

49%

49% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 44%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

1

Tracked since 21 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 21 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

19

19 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

19×

19 articles in the last 7 days; its usual week has 1.

Price $0.40 on 20 Nov 2026, -98% over 12 months (12-month range $0.40 to $25.02)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $0 in the last 12 months (the 12 months before: $20K).
Revenue per quarter. Revenue $0 in the latest quarter, -100% on a year earlier.
Capital spending per quarter. Capital spending $0 in the latest quarter, -100% on a year earlier.
Institutional holders (13F filers). 11 13F filers reported holding it in the latest 13F quarter, -8.3% on a year earlier.
Federal obligations. Federal obligations: $0 published in the last 12 months.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
20 Nov 20268-K and other filingsRegistered new securities for sale (S-1)
26 Aug 20268-K and other filingsPrivate placement of securities (Form D)
21 Aug 20268-K and other filingsRegistered new securities for sale (S-1)
3 Feb 20268-K and other filingsDirector or officer change
3 Feb 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Jan 20268-K and other filingsRegistered new securities for sale (S-1)
30 Dec 2025Sharp changeShort interest spike: short interest spike, 1.0M vs usual 141K (2025-12-15); 4.3x the same period a year earlier
2 Dec 2025Sharp changeShort interest spike: short interest spike, 780K vs usual 141K (2025-11-14); 1.1x the same period a year earlier
28 Oct 2025Sharp changeShort interest spike: short interest spike, 899K vs usual 138K (2025-10-15); 5.8x the same period a year earlier
14 Oct 2025Sharp changeShort interest spike: short interest spike, 1.4M vs usual 111K (2025-09-30); 23.9x the same period a year earlier
1 Oct 20258-K and other filingsRegistered new securities for sale (S-1)
25 Jul 20258-K and other filingsRegistered new securities for sale (S-1)
23 Jun 20258-K and other filingsChanged its auditor
16 Jun 20258-K and other filingsRegistered new securities for sale (S-1)
22 May 20258-K and other filingsDelisting notice or listing transfer
13 May 20258-K and other filingsRegistered new securities for sale (S-1)
18 Apr 20258-K and other filingsPrivate placement of securities (Form D)
1 Apr 20258-K and other filingsRegistered new securities for sale (S-1)
27 Mar 20258-K and other filingsRegistered new securities for sale (S-1)
27 Mar 20258-K and other filingsRegistered new securities for sale (S-1)
25 Mar 20258-K and other filingsRegistered new securities for sale (S-1)
3 Mar 20258-K and other filingsRegistered new securities for sale (S-1)
17 Dec 2024Sharp changeShort interest spike: short interest spike, 1.4M vs usual 93K (2024-11-29); 13.2x the same period a year earlier
3 Dec 2024Sharp changeShort interest spike: short interest spike, 735K vs usual 70K (2024-11-15); 27.3x the same period a year earlier
19 Nov 2024Sharp changeShort interest spike: short interest spike, 1.2M vs usual 70K (2024-10-31); 11.5x the same period a year earlier
30 Aug 20248-K and other filingsRegistered new securities for sale (S-1)
13 Aug 2024Sharp changeShort interest spike: short interest spike, 688K vs usual 83K (2024-07-31); 0.5x the same period a year earlier
30 Jul 2024Sharp changeShort interest spike: short interest spike, 668K vs usual 68K (2024-07-15); 18.9x the same period a year earlier
1 Jul 20248-K and other filingsDelisting notice or listing transfer
26 Jun 20248-K and other filingsRegistered new securities for sale (S-1)
14 Jun 20248-K and other filingsRegistered new securities for sale (S-1)
9 Apr 20248-K and other filingsRegistered new securities for sale (S-1)
29 Mar 20248-K and other filingsRegistered new securities for sale (S-1)
20 Mar 20248-K and other filingsRegistered new securities for sale (S-1)
15 Sep 20238-K and other filingsDelisting notice or listing transfer
15 Aug 2023Sharp changeShort interest spike: short interest spike, 1.4M vs usual 65K (2023-07-31); 16.7x the same period a year earlier
1 Aug 20238-K and other filingsRegistered new securities for sale (S-1)
14 Jul 20238-K and other filingsRegistered new securities for sale (S-1)
30 Jun 20238-K and other filingsRegistered new securities for sale (S-1)
30 Mar 20238-K and other filingsA major agreement ended
7 Mar 20238-K and other filingsDirector or officer change
7 Mar 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 Apr 20228-K and other filingsDelisting notice or listing transfer
21 Jan 20228-K and other filingsDirector or officer change
21 Jan 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Dec 2021Sharp changeShort interest spike: short interest spike, 1.1M vs usual 114K (2021-11-30); 4.0x the same period a year earlier
Insider net buying (open market)
Month from 1 Nov 2021: -$16.9M published
Month from 1 Jun 2022: $650 published
Month from 1 Nov 2025: $20K published
Revenue per quarter
Quarter ended 31 Dec 2021: $3.7M, +54% on a year earlier; public on 25 Mar 2022
Quarter ended 31 Mar 2022: $3.1M, +29% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $0, -100% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $0, -100% on a year earlier; public on 11 Nov 2022
Quarter ended 31 Dec 2022: $0, -100% on a year earlier; public on 31 Mar 2023
Capital spending per quarter
Quarter ended 31 Dec 2021: $118K; public on 25 Mar 2022
Quarter ended 30 Sep 2022: $4K, -69% on a year earlier; public on 11 Nov 2022
Quarter ended 31 Dec 2022: $0, -100% on a year earlier; public on 31 Mar 2023
Institutional holders (13F filers)
31 Dec 2021 report: 23; public on 14 Feb 2022
31 Mar 2022 report: 24; public on 16 May 2022
30 Jun 2022 report: 27; public on 15 Aug 2022
30 Sep 2022 report: 24; public on 14 Nov 2022
31 Dec 2022 report: 27; public on 14 Feb 2023
31 Mar 2023 report: 23; public on 15 May 2023
30 Jun 2023 report: 22; public on 14 Aug 2023
30 Sep 2023 report: 25; public on 14 Nov 2023
31 Dec 2023 report: 29; public on 14 Feb 2024
31 Mar 2024 report: 10; public on 15 May 2024
30 Jun 2024 report: 18; public on 14 Aug 2024
30 Sep 2024 report: 17; public on 14 Nov 2024
31 Dec 2024 report: 12; public on 14 Feb 2025
31 Mar 2025 report: 8; public on 15 May 2025
30 Jun 2025 report: 5; public on 14 Aug 2025
30 Sep 2025 report: 12; public on 14 Nov 2025
31 Dec 2025 report: 11; public on 17 Feb 2026
31 Mar 2026 report: 9; public on 15 May 2026
30 Jun 2026 report: 9; public on 14 Aug 2026
30 Sep 2026 report: 11; public on 16 Nov 2026
Federal obligations
Month from 1 Jan 2022: -$150K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is revenue, quarter at $0 (31 Dec 2022), none in the latest quarter; its normal quarter is $2.8M.
  • Insider net buying (open market): Insiders bought a net $0 in the last 12 months (the 12 months before: $20K).
  • Revenue per quarter: Revenue $0 in the latest quarter, -100% on a year earlier.
  • Capital spending per quarter: Capital spending $0 in the latest quarter, -100% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 29 insider trades

No trades in the last 90 days; the latest was filed 12 Nov 2025. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
12 Nov 2025Grady Grant IIIDirectorBuy13,513$1.49$20KForm 4
3 Jun 2022John NiederhuberDirectorBuy714$0.91$650Form 4
26 Nov 2021Tang Capital Partners LP and 2 othersExit FilingSell921,336$11.25$10.4MForm 4
22 Nov 2021Tang Capital Partners LP and 2 others10% ownerSell838,664$7.75$6.5MForm 4
6 Nov 2020Tang Capital Partners LP and 2 others10% ownerBuy1,436,675$17.30$24.8MForm 4
19 Aug 2019Randy Joe MadduxSVP Operations, CMOBuy25,000$0.76$19KForm 4
13 Aug 2019Fuad El-HibriDirectorBuy100,000$0.76$76KForm 4
30 Jul 2019Fuad El-HibriBoard of DirectorsBuy55,015$0.83$46KForm 4

11 institutions reported shares at the end of Q3 2026, 10% of the shares outstanding; 5 opened a position, 3 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Sabby Management, LLC233K6.72%$423KNew+233K
Hudson Bay Capital Management LP41K1.17%$74KNew+41K
Citadel Advisors LLC25K0.73%$46KNew+25K
Gsa Capital Partners LLP22K0.62%No change
Vanguard Capital Management LLC13K0.37%$23KNo change
Vanguard Fiduciary Trust Co4,1420.12%$8KNo change
Tower Research Capital LLC (TRC)1,9110.06%$3KNew+1,911
Osaic Holdings, Inc.3600.01%$664No change
SBI Securities Co., Ltd.1050.00%$191-4-3.7%
Caitong International Asset Management Co., Ltd30.00%$5New+3

Company events

All 89 company events

In 12 months: 6 major agreements, 3 share registrations, 1 director or officer change, 1 private placement. Results releases and routine reports are left out.

FiledWhat happenedSource
20 Nov 2026Registered new securities for sale (S-1)S-1
12 Nov 2026Warrant inducement letters: holders exercised 2,777,778 warrants at $1.08 for about $3.0M; new warrants for 13,888,890 shares issuedSame filing: sold shares privately8-K
23 Oct 2026Signed a major agreementSame filing: changed shareholder rights8-K
26 Aug 2026Private placement of securities (Form D)$3.5M sold of $3.5M offeredD
21 Aug 2026Registered new securities for sale (S-1)S-1
13 Aug 2026Signed a major agreementSame filing: sold shares privately8-K
30 Jun 2026Signed a major agreement8-K
27 May 2026Signed a major agreementSame filing: sold shares privately8-K

The 5 newest of 87 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 20 Nov 2026Filings record

    Registered new securities for sale (S-1)

  2. 26 Aug 2026Filings record

    Private placement of securities (Form D)

  3. 21 Aug 2026Filings record

    Registered new securities for sale (S-1)

  4. 3 Feb 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  5. 3 Feb 2026Filings record

    Director or officer change

  6. 28 Jan 2026Filings record

    Registered new securities for sale (S-1)

  7. 25 Dec 2025Short interest and volume change

    had 1.0M shares sold short in the 15 Dec 2025 report, 4.3× the same report last year.

    Same report last year: 242K; its normal report is 141K.

    See the evidence
    This period
    1.0M (the 15 Dec 2025 report)
    Normal report (median of 24 earlier)
    141K
    Typical spread (median absolute deviation)
    119K
    How far from its usual level
    +5.0
    Same report last year
    242K
    History used
    2,908 days
    2024-12-13: 242K2024-12-31: 19K2025-01-15: 27K2025-01-31: 44K2025-02-14: 23K2025-02-28: 60K2025-03-14: 121K2025-03-31: 387K2025-04-15: 704K2025-04-30: 452K2025-05-15: 418K2025-05-30: 9,3972025-06-13: 11K2025-06-30: 165K2025-07-15: 161K2025-07-31: 68K2025-08-15: 52K2025-08-29: 102K2025-09-15: 44K2025-09-30: 1.4M2025-10-15: 899K2025-10-31: 501K2025-11-14: 780K2025-11-28: 391K2025-12-15: 1.0M
    the 15 Dec 2025 report24 earlier reportsnormal: 141K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 26 Nov 2025Short interest and volume change

    had 780K shares sold short in the 14 Nov 2025 report, 1.1× the same report last year.

    Same report last year: 735K; its normal report is 141K.

    See the evidence
    This period
    780K (the 14 Nov 2025 report)
    Normal report (median of 24 earlier)
    141K
    Typical spread (median absolute deviation)
    119K
    How far from its usual level
    +3.6
    Same report last year
    735K
    History used
    2,877 days
    2024-11-15: 735K2024-11-29: 1.4M2024-12-13: 242K2024-12-31: 19K2025-01-15: 27K2025-01-31: 44K2025-02-14: 23K2025-02-28: 60K2025-03-14: 121K2025-03-31: 387K2025-04-15: 704K2025-04-30: 452K2025-05-15: 418K2025-05-30: 9,3972025-06-13: 11K2025-06-30: 165K2025-07-15: 161K2025-07-31: 68K2025-08-15: 52K2025-08-29: 102K2025-09-15: 44K2025-09-30: 1.4M2025-10-15: 899K2025-10-31: 501K2025-11-14: 780K
    the 14 Nov 2025 report24 earlier reportsnormal: 141K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 13 Nov 2025Insiders record

    Grant Grady III (director) bought 13,513 shares of APVO ($20,134) (dated 12 Nov 2025)

  10. 25 Oct 2025Short interest and volume change

    had 899K shares sold short in the 15 Oct 2025 report, 5.8× the same report last year.

    Same report last year: 155K; its normal report is 138K.

    See the evidence
    This period
    899K (the 15 Oct 2025 report)
    Normal report (median of 24 earlier)
    138K
    Typical spread (median absolute deviation)
    113K
    How far from its usual level
    +4.6
    Same report last year
    155K
    History used
    2,847 days
    2024-10-15: 155K2024-10-31: 1.2M2024-11-15: 735K2024-11-29: 1.4M2024-12-13: 242K2024-12-31: 19K2025-01-15: 27K2025-01-31: 44K2025-02-14: 23K2025-02-28: 60K2025-03-14: 121K2025-03-31: 387K2025-04-15: 704K2025-04-30: 452K2025-05-15: 418K2025-05-30: 9,3972025-06-13: 11K2025-06-30: 165K2025-07-15: 161K2025-07-31: 68K2025-08-15: 52K2025-08-29: 102K2025-09-15: 44K2025-09-30: 1.4M2025-10-15: 899K
    the 15 Oct 2025 report24 earlier reportsnormal: 138K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 10 Oct 2025Short interest and volume change

    had 1.4M shares sold short in the 30 Sep 2025 report, 24× the same report last year.

    Same report last year: 58K; its normal report is 111K.

    See the evidence
    This period
    1.4M (the 30 Sep 2025 report)
    Normal report (median of 24 earlier)
    111K
    Typical spread (median absolute deviation)
    86K
    How far from its usual level
    +10.0
    Same report last year
    58K
    History used
    2,832 days
    2024-09-30: 58K2024-10-15: 155K2024-10-31: 1.2M2024-11-15: 735K2024-11-29: 1.4M2024-12-13: 242K2024-12-31: 19K2025-01-15: 27K2025-01-31: 44K2025-02-14: 23K2025-02-28: 60K2025-03-14: 121K2025-03-31: 387K2025-04-15: 704K2025-04-30: 452K2025-05-15: 418K2025-05-30: 9,3972025-06-13: 11K2025-06-30: 165K2025-07-15: 161K2025-07-31: 68K2025-08-15: 52K2025-08-29: 102K2025-09-15: 44K2025-09-30: 1.4M
    the 30 Sep 2025 report24 earlier reportsnormal: 111K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 1 Oct 2025Filings record

    Registered new securities for sale (S-1)

  13. 25 Jul 2025Filings record

    Registered new securities for sale (S-1)

  14. 23 Jun 2025Filings record

    Changed its auditor

  15. 16 Jun 2025Filings record

    Registered new securities for sale (S-1)

  16. 22 May 2025Filings record

    Delisting notice or listing transfer

  17. 13 May 2025Filings record

    Registered new securities for sale (S-1)

  18. 18 Apr 2025Filings record

    Private placement of securities (Form D)

  19. 1 Apr 2025Filings record

    Registered new securities for sale (S-1)

  20. 27 Mar 2025Filings record

    Registered new securities for sale (S-1)

  21. 27 Mar 2025Filings record

    Registered new securities for sale (S-1)

  22. 25 Mar 2025Filings record

    Registered new securities for sale (S-1)

  23. 3 Mar 2025Filings record

    Registered new securities for sale (S-1)

  24. 11 Dec 2024Short interest and volume change

    had 1.4M shares sold short in the 29 Nov 2024 report, 13× the same report last year.

    Same report last year: 107K; its normal report is 93K.

    See the evidence
    This period
    1.4M (the 29 Nov 2024 report)
    Normal report (median of 24 earlier)
    93K
    Typical spread (median absolute deviation)
    68K
    How far from its usual level
    +13.0
    Same report last year
    107K
    History used
    2,527 days
    2023-11-30: 107K2023-12-15: 58K2023-12-29: 204K2024-01-12: 79K2024-01-31: 17K2024-02-15: 20K2024-02-29: 154K2024-03-15: 29K2024-03-28: 34K2024-04-15: 146K2024-04-30: 268K2024-05-15: 54K2024-05-31: 48K2024-06-14: 21K2024-06-28: 349K2024-07-15: 668K2024-07-31: 688K2024-08-15: 311K2024-08-30: 61K2024-09-13: 13K2024-09-30: 58K2024-10-15: 155K2024-10-31: 1.2M2024-11-15: 735K2024-11-29: 1.4M
    the 29 Nov 2024 report24 earlier reportsnormal: 93K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 27 Nov 2024Short interest and volume change

    had 735K shares sold short in the 15 Nov 2024 report, 27× the same report last year.

    Same report last year: 27K; its normal report is 70K.

    See the evidence
    This period
    735K (the 15 Nov 2024 report)
    Normal report (median of 24 earlier)
    70K
    Typical spread (median absolute deviation)
    52K
    How far from its usual level
    +8.6
    Same report last year
    27K
    History used
    2,513 days
    2023-11-15: 27K2023-11-30: 107K2023-12-15: 58K2023-12-29: 204K2024-01-12: 79K2024-01-31: 17K2024-02-15: 20K2024-02-29: 154K2024-03-15: 29K2024-03-28: 34K2024-04-15: 146K2024-04-30: 268K2024-05-15: 54K2024-05-31: 48K2024-06-14: 21K2024-06-28: 349K2024-07-15: 668K2024-07-31: 688K2024-08-15: 311K2024-08-30: 61K2024-09-13: 13K2024-09-30: 58K2024-10-15: 155K2024-10-31: 1.2M2024-11-15: 735K
    the 15 Nov 2024 report24 earlier reportsnormal: 70K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 13 Nov 2024Short interest and volume change

    had 1.2M shares sold short in the 31 Oct 2024 report, 12× the same report last year.

    Same report last year: 104K; its normal report is 70K.

    See the evidence
    This period
    1.2M (the 31 Oct 2024 report)
    Normal report (median of 24 earlier)
    70K
    Typical spread (median absolute deviation)
    50K
    How far from its usual level
    +15.3
    Same report last year
    104K
    History used
    2,498 days
    2023-10-31: 104K2023-11-15: 27K2023-11-30: 107K2023-12-15: 58K2023-12-29: 204K2024-01-12: 79K2024-01-31: 17K2024-02-15: 20K2024-02-29: 154K2024-03-15: 29K2024-03-28: 34K2024-04-15: 146K2024-04-30: 268K2024-05-15: 54K2024-05-31: 48K2024-06-14: 21K2024-06-28: 349K2024-07-15: 668K2024-07-31: 688K2024-08-15: 311K2024-08-30: 61K2024-09-13: 13K2024-09-30: 58K2024-10-15: 155K2024-10-31: 1.2M
    the 31 Oct 2024 report24 earlier reportsnormal: 70K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  27. 30 Aug 2024Filings record

    Registered new securities for sale (S-1)

  28. 10 Aug 2024Short interest and volume change

    had 688K shares sold short in the 31 Jul 2024 report, 51% below the same report last year.

    Same report last year: 1.4M; its normal report is 83K.

    See the evidence
    This period
    688K (the 31 Jul 2024 report)
    Normal report (median of 24 earlier)
    83K
    Typical spread (median absolute deviation)
    53K
    How far from its usual level
    +7.8
    Same report last year
    1.4M
    History used
    2,406 days
    2023-07-31: 1.4M2023-08-15: 31K2023-08-31: 86K2023-09-15: 46K2023-09-29: 120K2023-10-13: 129K2023-10-31: 104K2023-11-15: 27K2023-11-30: 107K2023-12-15: 58K2023-12-29: 204K2024-01-12: 79K2024-01-31: 17K2024-02-15: 20K2024-02-29: 154K2024-03-15: 29K2024-03-28: 34K2024-04-15: 146K2024-04-30: 268K2024-05-15: 54K2024-05-31: 48K2024-06-14: 21K2024-06-28: 349K2024-07-15: 668K2024-07-31: 688K
    the 31 Jul 2024 report24 earlier reportsnormal: 83K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  29. 25 Jul 2024Short interest and volume change

    had 668K shares sold short in the 15 Jul 2024 report, 19× the same report last year.

    Same report last year: 35K; its normal report is 68K.

    See the evidence
    This period
    668K (the 15 Jul 2024 report)
    Normal report (median of 24 earlier)
    68K
    Typical spread (median absolute deviation)
    40K
    How far from its usual level
    +10.0
    Same report last year
    35K
    History used
    2,390 days
    2023-07-14: 35K2023-07-31: 1.4M2023-08-15: 31K2023-08-31: 86K2023-09-15: 46K2023-09-29: 120K2023-10-13: 129K2023-10-31: 104K2023-11-15: 27K2023-11-30: 107K2023-12-15: 58K2023-12-29: 204K2024-01-12: 79K2024-01-31: 17K2024-02-15: 20K2024-02-29: 154K2024-03-15: 29K2024-03-28: 34K2024-04-15: 146K2024-04-30: 268K2024-05-15: 54K2024-05-31: 48K2024-06-14: 21K2024-06-28: 349K2024-07-15: 668K
    the 15 Jul 2024 report24 earlier reportsnormal: 68K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 1 Jul 2024Filings record

    Delisting notice or listing transfer

  31. 26 Jun 2024Filings record

    Registered new securities for sale (S-1)

  32. 14 Jun 2024Filings record

    Registered new securities for sale (S-1)

  33. 9 Apr 2024Filings record

    Registered new securities for sale (S-1)

  34. 29 Mar 2024Filings record

    Registered new securities for sale (S-1)

  35. 20 Mar 2024Filings record

    Registered new securities for sale (S-1)

  36. 15 Sep 2023Filings record

    Delisting notice or listing transfer

  37. 10 Aug 2023Short interest and volume change

    had 1.4M shares sold short in the 31 Jul 2023 report, 17× the same report last year.

    Same report last year: 83K; its normal report is 65K.

    See the evidence
    This period
    1.4M (the 31 Jul 2023 report)
    Normal report (median of 24 earlier)
    65K
    Typical spread (median absolute deviation)
    25K
    How far from its usual level
    +26.6
    Same report last year
    83K
    History used
    2,040 days
    2022-07-29: 83K2022-08-15: 43K2022-08-31: 41K2022-09-15: 42K2022-09-30: 53K2022-10-14: 57K2022-10-31: 61K2022-11-15: 53K2022-11-30: 52K2022-12-15: 449K2022-12-30: 275K2023-01-13: 186K2023-01-31: 135K2023-02-15: 69K2023-02-28: 150K2023-03-15: 105K2023-03-31: 141K2023-04-14: 92K2023-04-28: 136K2023-05-15: 71K2023-05-31: 51K2023-06-15: 21K2023-06-30: 31K2023-07-14: 35K2023-07-31: 1.4M
    the 31 Jul 2023 report24 earlier reportsnormal: 65K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  38. 1 Aug 2023Filings record

    Registered new securities for sale (S-1)

  39. 14 Jul 2023Filings record

    Registered new securities for sale (S-1)

  40. 30 Jun 2023Filings record

    Registered new securities for sale (S-1)

Showing the newest 40 of 106 entries; narrow the window or the kind of data to see older ones.

Not listed: 185 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001671584
Ticker
APVO
Domain
aptevotherapeutics.com
Hq location
WA|SEATTLE|98121 (1 unverified)
Name
Aptevo Research and Development LLC, Aptevo Therapeutics Inc, apvo-ex21_1.htm, EX-21.1
Uei
NRJ4JHZH49N6
  • SEC Form 13F institutional holdings369 data points30 Sep 2016 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)230 records2 Aug 2016 to 20 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)644 data points31 Dec 2014 to 16 Nov 2026
  • SEC Form 4 insider transactions29 records, 104 data points8 Dec 2017 to 12 Nov 2025
  • FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards6 data points5 Aug 2021 to 30 Dec 2021